IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

Ruggero Capra, Alessandra Sottini, Cinzia Cordioli, Federico Serana, Marco Chiarini, Luigi Caimi, Alessandro Padovani, Roberto Bergamaschi, Luisa Imberti

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Anti-IFNβ antibodies are related to IFNβ bioavailability loss in multiple sclerosis. We investigated the reliability of radioimmunoprecipitation and cytopathic assays in detecting binding (BAbs) and neutralizing (NAbs) antibodies and the correlation of these antibodies to MxA mRNA production. Eleven percent of IFNβ-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. Some patients had contemporary MxA induction in the presence of high NAb titres, thus calling into question the reliability of cytopathic assay. Since anti-IFNβ antibodies well correlated with MxA induction loss, MxA assay is an appropriate test to determine IFNβ bioavailability.

Original languageEnglish
Pages (from-to)102-110
Number of pages9
JournalJournal of Neuroimmunology
Volume189
Issue number1-2
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Biological Availability
Multiple Sclerosis
Anti-Idiotypic Antibodies
Radioimmunoprecipitation Assay
Messenger RNA
Antibodies
Neutralizing Antibodies

Keywords

  • BAbs
  • Bioavailability
  • Interferons
  • Multiple sclerosis
  • MxA
  • NAbs

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Capra, R., Sottini, A., Cordioli, C., Serana, F., Chiarini, M., Caimi, L., ... Imberti, L. (2007). IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. Journal of Neuroimmunology, 189(1-2), 102-110. https://doi.org/10.1016/j.jneuroim.2007.06.006

IFNβ bioavailability in multiple sclerosis patients : MxA versus antibody-detecting assays. / Capra, Ruggero; Sottini, Alessandra; Cordioli, Cinzia; Serana, Federico; Chiarini, Marco; Caimi, Luigi; Padovani, Alessandro; Bergamaschi, Roberto; Imberti, Luisa.

In: Journal of Neuroimmunology, Vol. 189, No. 1-2, 09.2007, p. 102-110.

Research output: Contribution to journalArticle

Capra, R, Sottini, A, Cordioli, C, Serana, F, Chiarini, M, Caimi, L, Padovani, A, Bergamaschi, R & Imberti, L 2007, 'IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays', Journal of Neuroimmunology, vol. 189, no. 1-2, pp. 102-110. https://doi.org/10.1016/j.jneuroim.2007.06.006
Capra, Ruggero ; Sottini, Alessandra ; Cordioli, Cinzia ; Serana, Federico ; Chiarini, Marco ; Caimi, Luigi ; Padovani, Alessandro ; Bergamaschi, Roberto ; Imberti, Luisa. / IFNβ bioavailability in multiple sclerosis patients : MxA versus antibody-detecting assays. In: Journal of Neuroimmunology. 2007 ; Vol. 189, No. 1-2. pp. 102-110.
@article{06026527a1c14fba94b1a4431f78b618,
title = "IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays",
abstract = "Anti-IFNβ antibodies are related to IFNβ bioavailability loss in multiple sclerosis. We investigated the reliability of radioimmunoprecipitation and cytopathic assays in detecting binding (BAbs) and neutralizing (NAbs) antibodies and the correlation of these antibodies to MxA mRNA production. Eleven percent of IFNβ-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. Some patients had contemporary MxA induction in the presence of high NAb titres, thus calling into question the reliability of cytopathic assay. Since anti-IFNβ antibodies well correlated with MxA induction loss, MxA assay is an appropriate test to determine IFNβ bioavailability.",
keywords = "BAbs, Bioavailability, Interferons, Multiple sclerosis, MxA, NAbs",
author = "Ruggero Capra and Alessandra Sottini and Cinzia Cordioli and Federico Serana and Marco Chiarini and Luigi Caimi and Alessandro Padovani and Roberto Bergamaschi and Luisa Imberti",
year = "2007",
month = "9",
doi = "10.1016/j.jneuroim.2007.06.006",
language = "English",
volume = "189",
pages = "102--110",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - IFNβ bioavailability in multiple sclerosis patients

T2 - MxA versus antibody-detecting assays

AU - Capra, Ruggero

AU - Sottini, Alessandra

AU - Cordioli, Cinzia

AU - Serana, Federico

AU - Chiarini, Marco

AU - Caimi, Luigi

AU - Padovani, Alessandro

AU - Bergamaschi, Roberto

AU - Imberti, Luisa

PY - 2007/9

Y1 - 2007/9

N2 - Anti-IFNβ antibodies are related to IFNβ bioavailability loss in multiple sclerosis. We investigated the reliability of radioimmunoprecipitation and cytopathic assays in detecting binding (BAbs) and neutralizing (NAbs) antibodies and the correlation of these antibodies to MxA mRNA production. Eleven percent of IFNβ-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. Some patients had contemporary MxA induction in the presence of high NAb titres, thus calling into question the reliability of cytopathic assay. Since anti-IFNβ antibodies well correlated with MxA induction loss, MxA assay is an appropriate test to determine IFNβ bioavailability.

AB - Anti-IFNβ antibodies are related to IFNβ bioavailability loss in multiple sclerosis. We investigated the reliability of radioimmunoprecipitation and cytopathic assays in detecting binding (BAbs) and neutralizing (NAbs) antibodies and the correlation of these antibodies to MxA mRNA production. Eleven percent of IFNβ-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. Some patients had contemporary MxA induction in the presence of high NAb titres, thus calling into question the reliability of cytopathic assay. Since anti-IFNβ antibodies well correlated with MxA induction loss, MxA assay is an appropriate test to determine IFNβ bioavailability.

KW - BAbs

KW - Bioavailability

KW - Interferons

KW - Multiple sclerosis

KW - MxA

KW - NAbs

UR - http://www.scopus.com/inward/record.url?scp=34548590673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548590673&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.06.006

DO - 10.1016/j.jneuroim.2007.06.006

M3 - Article

C2 - 17619058

AN - SCOPUS:34548590673

VL - 189

SP - 102

EP - 110

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -